Future directions of OHDSI

George Hripcsak MD MS
Director, Columbia University OHDSI Coordinating Center
Professor and Chair of Biomedical Informatics
Columbia University Irving Medical Center
NewYork-Presbyterian Hospital

Patrick Ryan PhD
Johnson & Johnson
Columbia University Irving Medical Center
OHDSI’s mission

To improve health by empowering a community to collaboratively generate the evidence that promotes better health decisions and better care
To improve health by empowering a community to collaboratively generate the evidence that promotes better health decisions and better care.
Complementary evidence to inform the patient journey

Clinical characterization: What happened to them?

Patient-level prediction: What will happen to me?

Population-level effect estimation: What are the causal effects?

Observation

Inference

Causal inference
Idea #1: HowOften.org

• Opportunity: Provide evidence to understand the absolute risk of adverse events
• Solution: Large-scale characterization of incidence of outcomes following drug exposure
  – Targets: New users of ingredient, for all ingredients
  – Outcomes: Event starts, for all adverse events
  – Time-at-risk: 30-day, on-treatment, intent-to-treat?
  – Results: Incidence proportion and rates, per database and prediction interval via meta-analysis
  – Dissemination: Interactive dashboard to allow user to search for drug and outcome
• Open questions:
  – Targets: Nested within indications?
  – Outcomes: 1st occurrence vs. all occurrence of outcomes? Phenotypes vs. codes?
  – Results: Stratify by age/sex/year?
  – Dissemination: How to show failures from objective database/cohort diagnostics?
Idea #2: Safety of Interventions Real-world Evidence Network (SIREN)

- Opportunity: Provide evidence to support international pharmacovigilance activities to identify and evaluate the relative risk of adverse events associated with drug exposure
- Solution: Large-scale estimation of outcomes following drug exposure
  - Apply LEGEND principles to compare treatments within same indication
  - Methods: Comparative cohort, Self-controlled case series
  - Time-at-risk: 30-day, on-treatment
  - Results: Discovery: Multiplicity-adjusted hypothesis testing; Estimation: Calibrated confidence intervals for all analyses that pass objective diagnostics
  - Dissemination: Interactive dashboard to allow user to search for drug and outcome, or explore all drugs/all outcomes
- Open questions:
  - Targets: Which indications?
  - Outcomes: Which outcomes?
  - Dissemination: How to show failures from objective database/cohort/study diagnostics?
Idea #3: Heterogeneity of treatment effects in comparative effectiveness

• Opportunity: Provide evidence to estimate effects within subpopulations of interest
• Solution: Large-scale estimation of outcomes following drug exposure
  – Apply LEGEND principles to compare treatments within same indication
  – Methods: Comparative cohort
  – Time-at-risk: on-treatment
  – Results: Estimation: Calibrated confidence intervals for all analyses that pass objective diagnostics
  – Dissemination: Interactive dashboard to allow user to search for drug and outcome, or explore all drugs/all outcomes
• Open questions:
  – Targets: Which indications? T2DM, then what?
  – Outcomes: Which outcomes for each indication?
  – Subgroups: which subpopulations: pre-defined (age: , sex, race, hepatic/renal impaired) or empirically derived?
Idea #4: Whatllhappentome.org

- Opportunity: Provide evidence to personalize risk of outcomes following treatment initiation
- Solution: Large-scale prediction of outcomes following drug exposure
  - Targets: New users of ingredient, for all ingredients
  - Outcomes: Event starts, for all adverse events
  - Time-at-risk: 30-day, 1-year post-exposure
  - Results: Model performance (discrimination, calibration)
  - Dissemination: Interactive dashboard to allow user to enter baseline characteristics and see personalized risk of outcome post-exposure
- Open questions:
  - How to use prediction results: absolute risk vs. counterfactual prediction?
Foundational elements to enable reliable evidence generation

Clinical characterization: What happened to them?

Patient-level prediction: What will happen to me?

Population-level effect estimation: What are the causal effects?

Evidence use cases:

Foundational pillars:

- Standardized vocabularies
- Standardized data network
- Standardized open-source tools
Pillar #1: Standardized vocabularies

• Opportunity: Increase transparency and maturity with vocabulary development and evaluation process

• Proposed solutions:
  – Conduct landscape assessment to understand community needs
  – Develop code of conduct and developer guidelines
  – Disseminate vocabulary process and end-user documentation and roadmap
  – Establish centralized development infrastructure
  – Create standardized test development
  – Build vocabulary version release distribution service
Pillar #2: Standardized data network

• Opportunity: Increase transparency and maturity of OHDSI data network

• Proposed solutions:
  – Create OHDSI data network catalog to encourage network studies across interested partners and promote data quality practices
  – Generate OHDSI network concept prevalence data and make accessible for ATLAS users to enable more generalizable phenotype development
  – Promote database diagnostics by having data partners share limited subset of ACHILLES to allow for users to identify databases that satisfy study criteria
Pillar #3: Standardized open-source tools

• Opportunity: Increase adoption and ease-of-use of HADES packages and other OHDSI open-source analytic tools

• Proposed solutions:
  – Create central infrastructure to enable testing of all OHDSI tools against each of the supporting database platforms
  – Establish referent benchmark study that all organizations can execute to demonstrate that OHDSI toolstack is operational
  – Improve documentation and educational materials to promote adoption of OHDSI tools
  – Encourage greater community support of open-source development activities: we need more help to maintain our solutions!
What are your reactions/comments/questions to the proposed directions for OHDSI?

No responses received yet. They will appear here...
Which direction are you most excited about?

Characterization idea: HowOften.org

Estimation idea: SIREN for pharmacovigilance

Estimation idea: Heterogeneity of treatment effects in comparative effectiveness

Prediction idea: WhatIHappenedtoMe.org

Pillar: Standardized vocabularies

Pillar: Standardized data network

Pillar: Standardized open-source tools